Trial Profile
A prospective, open label, randomized, controlled trial for evaluation of the safety and efficacy of Apatinib mesylate tablets combined with docetaxel in the treatment of metastatic breast cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Jun 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 11 Jun 2018 New trial record